FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308739962> ?p ?o ?g. }

• W4308739962 endingPage "103924" @default.
• W4308739962 startingPage "103924" @default.
• W4308739962 abstract "Breast cancer (BC) is a disease detected in thousands of women worldwide every year. BC is classified into four subtypes: Luminal A, luminal B, Her2 and triple-negative. The triple-negative (TN) is the most aggressive one, causing a poor prognosis. Traditional therapies such as surgery, chemotherapy, and radiation are usually used as treatment. However, those are not site-directed (exclusive of cancer cells), and they cause damage to adjacent healthy tissues; thus, causing diverse side effects. Nowadays, potential epigenetic regulators including HDAC inhibitors (HDACIs), DNMT inhibitors (DNMTIs), small interfering RNAs (siRNAs) and microRNAs (miRNAs) have been proposed to treat Triple-Negative Breast Cancer (TN-BC), showing excellent results in terms of apoptosis, sensitivity to therapeutic agents, and decreased epithelial mesenchymal transition (EMT) in tumor cells. However, epigenetic regulators exhibit some disadvantage like low stability and high probability of being degraded in the bloodstream. Therefore, researchers have proposed the use of nano-vehicles that are site-directed to transport them to cancer cells, providing a safe environment for epigenetic regulators and avoiding damage to adjacent healthy tissues. In this review, we describe carrier nanoparticles of epigenetic regulators to treat TN-BC tumors. Furthermore, we describe the nanomaterials used for the construction of nano-vehicles, delivery mechanisms, and genes/pathways regulated by epigenetic regulators. Finally, the limitations to overcome in order to apply this type of therapy in the clinic." @default.
• W4308739962 created "2022-11-15" @default.
• W4308739962 creator A5025708990 @default.
• W4308739962 creator A5043578051 @default.
• W4308739962 creator A5048898700 @default.
• W4308739962 creator A5060198404 @default.
• W4308739962 creator A5068575095 @default.
• W4308739962 date "2022-11-01" @default.
• W4308739962 modified "2023-10-16" @default.
• W4308739962 title "Nano-vehicles modulated delivery of therapeutic epigenetic regulators to treat Triple-Negative Breast Cancer" @default.
• W4308739962 cites W1983148605 @default.
• W4308739962 cites W1988055795 @default.
• W4308739962 cites W2053708409 @default.
• W4308739962 cites W2066222211 @default.
• W4308739962 cites W2092476693 @default.
• W4308739962 cites W2190204638 @default.
• W4308739962 cites W2191264984 @default.
• W4308739962 cites W2202983172 @default.
• W4308739962 cites W2221696309 @default.
• W4308739962 cites W2303810752 @default.
• W4308739962 cites W2513599763 @default.
• W4308739962 cites W2518419687 @default.
• W4308739962 cites W2519786994 @default.
• W4308739962 cites W2527653523 @default.
• W4308739962 cites W2547420156 @default.
• W4308739962 cites W2552680036 @default.
• W4308739962 cites W2567652734 @default.
• W4308739962 cites W2606125928 @default.
• W4308739962 cites W2606785274 @default.
• W4308739962 cites W2626332084 @default.
• W4308739962 cites W2738735913 @default.
• W4308739962 cites W2745867083 @default.
• W4308739962 cites W2769426045 @default.
• W4308739962 cites W2769964316 @default.
• W4308739962 cites W2789200989 @default.
• W4308739962 cites W2790269192 @default.
• W4308739962 cites W2790751428 @default.
• W4308739962 cites W2795615449 @default.
• W4308739962 cites W2801012801 @default.
• W4308739962 cites W2801777904 @default.
• W4308739962 cites W2805380134 @default.
• W4308739962 cites W2809388839 @default.
• W4308739962 cites W2809498459 @default.
• W4308739962 cites W2890626270 @default.
• W4308739962 cites W2893451195 @default.
• W4308739962 cites W2893671817 @default.
• W4308739962 cites W2895674574 @default.
• W4308739962 cites W2896909322 @default.
• W4308739962 cites W2904623992 @default.
• W4308739962 cites W2905038838 @default.
• W4308739962 cites W2905111869 @default.
• W4308739962 cites W2910175501 @default.
• W4308739962 cites W2913419794 @default.
• W4308739962 cites W2913470021 @default.
• W4308739962 cites W2918127702 @default.
• W4308739962 cites W2936582736 @default.
• W4308739962 cites W2940988485 @default.
• W4308739962 cites W2941437497 @default.
• W4308739962 cites W2943106036 @default.
• W4308739962 cites W2951417311 @default.
• W4308739962 cites W2953849769 @default.
• W4308739962 cites W2957984348 @default.
• W4308739962 cites W2975605493 @default.
• W4308739962 cites W2976269700 @default.
• W4308739962 cites W2982780080 @default.
• W4308739962 cites W2990582951 @default.
• W4308739962 cites W2990899603 @default.
• W4308739962 cites W2991855137 @default.
• W4308739962 cites W2991922517 @default.
• W4308739962 cites W2995898384 @default.
• W4308739962 cites W3004039824 @default.
• W4308739962 cites W3015270399 @default.
• W4308739962 cites W3026323285 @default.
• W4308739962 cites W3038021743 @default.
• W4308739962 cites W3045441629 @default.
• W4308739962 cites W3081020835 @default.
• W4308739962 cites W3087674383 @default.
• W4308739962 cites W3092136373 @default.
• W4308739962 cites W3093405310 @default.
• W4308739962 cites W3094447257 @default.
• W4308739962 cites W3096239350 @default.
• W4308739962 cites W3109769703 @default.
• W4308739962 cites W3112235049 @default.
• W4308739962 cites W3113041522 @default.
• W4308739962 cites W3115415554 @default.
• W4308739962 cites W3120141853 @default.
• W4308739962 cites W3120536998 @default.
• W4308739962 cites W3124398730 @default.
• W4308739962 cites W3127675401 @default.
• W4308739962 cites W3128663841 @default.
• W4308739962 cites W3129058300 @default.
• W4308739962 cites W3129805177 @default.
• W4308739962 cites W3134531697 @default.
• W4308739962 cites W3136088558 @default.
• W4308739962 cites W3137068775 @default.
• W4308739962 cites W3156107948 @default.
• W4308739962 cites W3159765728 @default.
• W4308739962 cites W3162871690 @default.

• next